Prostate cancer is the most common cancer in men accounting for around 24% of all male cancers in United Kingdom. The role of chemotherapy in the neoadjuvant and adjuvant setting is still unclear despite considerable progress in this area. Chemotherapy for advanced prostate cancer has become the standard of care, however options of treatment following taxotere failure are still limited. This review summarizes recent advances in chemotherapy treatment options for early as well as advanced prostate cancer.